Access Dermatology

Breaking News

• Breaking News List »

Switching from etanercept to adalimumab: results in psoriasis patients with primary or secondary failure or intolerance to etanercept

Two prospective Dutch registries were used to evaluate 30 psoriasis patients with primary or secondary failure or intolerance to etanercept after switching to a 48-week treatment with adalimumab at a mean weekly dose of 23 mg. Primary failure with etanercept was defined as insufficient response, a failure to achieve a decrease in the Psoriasis Area and Severity Index (PASI) by 50% (PASI 50) at week 12. Secondary failure was described as a loss of response to etanercept (PASI 50) at week 12 and intolerance as cessation of etanercept treatment due to adverse events. The primary endpoints were the percentage of patients achieving PASI 50 or PASI 75. Of 11 patients ...